To evaluate the effects of tamsulosin, solifenacin, and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling Double-J (DJ) ureteral stents.
INTRODUCTION
The use of ureteral stents in surgery was described as early as the 19th century [1] . Zimskind, however, in 1967 was the first to describe the cystoscopic placement of indwelling ureteral stents for obstructed ureters [2] (Zimskind et al, 1967 ). The first "double-J" (DJ) or double pigtail stent was developed almost simultaneously by Finney and Hepperlen [3] (Finney, 1978; Hepperlen et al, 1978) . The use of DJ stents increased dramatically in urology departments worldwide, which had a tremendous positive impact on endourologic surgery and patient care. Today, ureteral stents are of fundamental importance to any urologic practice.
The double-J stent, which is the most common form of ureteral stent, is used in obstructive pyelonephritis, intolerable acute renal colic, ureteral edema, ureter perforation following endoscopic procedures, and diseases such as steinstrasse [4, 5] . The patients experience various stent-related symptoms, such as pain, frequency, and urgency causing significant decrease in patient quality of life in both genders [6] . The etiology of these symptoms is unknown. Thomas in year 1993 reported that an important factor of stent-related symptoms is the reflux of urine due to pressure transmitted to the renal pelvis during urination, smooth muscle spasm and trigonal mucosal irritation by the intravesicular part of the stent [7] .
For this reason, several attempts to minimize stent-related symptoms have recently been reported.
Thus the pharmacologic management with selective alpha-1-blockers and antimuscarinic agents believed to be simpler and less invasive than other ways.
Tamsulosin [8, 9] acts as a selective inhibitor of α-1a/1d-mediated contraction of the smooth muscles in distal ureter, bladder trigone, and bladder neck. It is thought that relaxing these smooth muscles decreases bladder outlet resistance and voiding pressure, with beneficial effect on stent related LUTS. Solifenacin [10, 11, 12] acts as a muscarinic receptor antagonist used for treatment of patients with overactive bladder (OAB) and might be effective as well for stentrelated symptoms. The purpose of this article was therefore to analyze and assess the effectiveness of a selective alpha-1-blocker (tamsulosin) in combination with antimuscarinic (solifenacin) in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.
MATERIALS AND METHODS

Materials
During the period from January 2018 to December 2018, 295 patients were selected and 21 of them underwent bilateral DJ stenting who were excluded and 274 patients (195 men &79 women) underwent DJ Stenting anterogradely and retrogradely by a single surgeon in the Department of Urology at K.R Hospital, MMC&RI, Mysore and CSI HMH, Mysore with required eligibility criteria were considered in this study.
Eligibility Criteria
Inclusion Criteria
Patients aged more than 18 years undergoing Double-J stenting for urinary tract calculi were included in the study. These underwent thorough clinical, general, systemic examinations and the required investigational procedures to exclude any neurological, organic and systemic cause for their symptoms. Only those patients who had no obvious neurological, organic and systemic causes were included in the study.
Exclusion Criteria
Patients who met the following criteria were excluded from the study:  Previous use of selective alpha-1-blocker and/or antimuscarinic agent or hypersenisitivity to one or more alpha blockers.
Methods
On the screening visit detailed history, general examination and detailed urological examination was carried out and the enrolled patients were worked up as per protocol and data was recorded in data sheet. The surgery was performed under general/spinal anesthesia. A 5/5.5 Fr polyurethane ureteral stents were used in all patients. The position of the stent was confirmed by fluoroscopy. A total of 274 patients were chosen after assessing inclusion/exclusion criteria.
The patients were randomized into four groups:
 Group 1(n= 69) was the control group and did not take any drugs.
 Group 2(n= 66) received tamsulosin 0.4 mg once a day every day.
 Group 3(n= 67) received solifenacin 5 mg once a day every day.
 Group4 (n= 72) received tamsulosin 0.4 mg and solifenacin 5 mg in combination daily.
Patients Assessment and Outcome Measurements
The day before surgery, on postoperative day 1 and on the on postoperative day 14, each patient completed written International Prostate Symptom Score/quality of life (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires.
The IPSS was divided into the total score, obstructive symptom score, and irritative To Evaluate the Effects of Tamsulosin, Solifenacin and Combination Therapy for the Treatment of Ureteral Stent Associated Symptoms symptom score, and each was compared. Visual Analogue Pain Scale graded from 1(minimal or no symptoms) to 10 (symptoms of maximal severity). Each group's preoperative day, postoperative day 1 and post operative day 14 scores were compared.
Statistical analyses were performed with SPSS ver.18.0 (SPSS Inc., Chicago, IL, USA). Chisquare test, one way ANOVA, and one way repeated measure ANOVA were used for comparision between each of four groups. Values of p< 0.05 were considered statistically significant.
RESULTS
This study was a prospective, randomized and comparative study carried out between January 2018 and December 2018 to evaluate the effect of tamsulosin, solifenacin and combination therapy of the two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.
A total of 295 patients were enrolled in the study and 21 patients who underwent bilateral stenting were excluded and 274 patients completed the study.
 Group 1(n=69) was the control group and did not take any drugs.
 Group 2(n=66) received tamsulosin 0.4 mg once a day every day.
 Group 3(n=67) received solifenacin 5 mg once a day every day.
 Group 4(n=72) received tamsulosin 0.4 mg and solifenacin 5 mg in combination daily.
The mean age of the patients was 39.22 ± 11.92 years, and there were no significant differences between the groups. A total of 182 patients underwent URSL and 92 patients underwent PCNL.There were statistically significant differences in the IPSS total score and the obstructive sub score by one-way repeatedmeasures ANOVA (p=0.013, 0.006).
There were significant differences between group 1 and group 4 (p=0.015), and between group 2 and group 4 (p=0.031), in the IPSS total score. For the obstructive subscore, group 4 differed significantly from group 1 (p=0.003). There were no statistically significant differences in the irritative sub score, QoL, or VAPS (p=0.075, 0.068, and 0.088, respectively). However, the pvalue of interaction was statistically significant for the IPSS total score, irritative subscore, obstructive subscore, and QoL (p<0.001, <0.001, 0.015, and 0.012, respectively).
We therefore compared each group by one-way ANOVA at each time point. On the day of stent removal, all scores were significantly different in each group except the VAPS (p<0.001, <0.001, <0.001, <0.001). In particular, all scores were significantly lower in group 4 except for VAPS. In group 2, only the obstructive score was significantly lower. The total and irritative sub score were significantly lower in group 3. Preoperatively and 1 day postoperatively, there were no significant differences in any group. The VAPS did not appear to significantly change in any groups ( Table 2) . According to the multiple comparison test on the day of stent removal, there was a significant decrease only in group 4. This suggests that that stent-related symptoms improved more in group 4 than in group 1. Symptoms did not significantly improve in the other groups. The side effects of tamsulosin and solifenacin were minimal. No patients discontinued the medication because of side effects. The mean age of the patients was 39.22 ± 11.92 years, and there were no significant differences between the groups ( Table 1 ). As seen in Table  2 main indication of ureteral double -J stent placement was URS and PCNL, out of total 274 patients maximum no of patients 66.42% (182 out of 274) were URS cases and 33.58% (92 out of 272) were PCNL cases. Between the two groups p-value was 0.8351 which was insignificant. There were statistically significant differences in the IPSS total score and the obstructive subscore by one-way repeatedmeasures ANOVA (p=0.013, 0.006). There were significant differences between group 1 and group 4 (p=0.015), and between group 2 and group 4 (p=0.031), in the IPSS total score. For the obstructive subscore, group 4 differed significantly from group 1 (p=0.003). There were no statistically significant differences in the irritative subscore, QoL, or VAPS (p=0.075, 0.068, and 0.088, respectively). However, the pvalue of interaction was statistically significant for the IPSS total score, irritative subscore, obstructive subscore, and QoL (p<0.001, <0.001, 0.015, and 0.012, respectively).
We therefore compared each group by one-way ANOVA at each time point. On the day of stent removal, all scores were significantly different in each group except the VAPS (p<0.001, <0.001, <0.001, <0.001). In particular, all scores were significantly lower in group 4 except for VAPS.
In group 2, only the obstructive score was significantly lower. The total and irritative subscore were significantly lower in group 3. Preoperatively and 1 day postoperatively, there were no significant differences in any group. The VAPS did not appear to significantly change in any groups (Table 3 ). According to the multiple comparison test on the day of stent removal, there was a significant decrease only in group 4. This suggests that those stent-related symptoms improved more in group 4 than in group 1. Symptoms did not significantly improve in the other groups. The side effects of tamsulosin and solifenacin were minimal. No patients discontinued the medication because of side effects.
DISCUSSION
The present study was a prospective, randomized and comparative study carried out between January 2018 and December 2018 in the Department of Urology, at K.R Hospital MMC&RI, Mysore and CSI HMH, Mysore to evaluate the effect of tamsulosin, solifenacin and combination therapy of the two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.
A total of 295 patients were enrolled in the study and 21 patients who underwent bilateral  Group 1(n=69) was the control group and did not take any drugs.
The results of this prospective, randomized, controlled trial showed that, the combined use of tamsulosin and solifenacin improved the QoL and alleviated LUTS associated with double-J ureteral stents, better than either drug alone and well tolerated.
Stent discomfort is believed to affect over 80% of patients [13, 14, 15, 16] . Patients with indwelling stents have been known to complain of a variety of stent-related symptoms, typically: storage, voiding, OAB symptoms, haematuria, and pain. These symptoms are believed to be unavoidable and associated with reduced healthrelated quality of life.
Damiano et al [8] reported that there was no symptoms difference between stent with different size, whereas there was a tendency of small diameter stents to dislodge more often.
Chew et al [17] reported that changing in body position led to movement of distal end within the bladder and induced more trigonal irritation and stent related symptoms.
Lang and associates [18] stated that a possible mechanism of relief of stent-related symptoms could be smooth muscle relaxation of lower ureter and trigone as well as reducing ureteric motility.
Wang and his colleagues [19] suggested that relaxation of bladder neck/prostatic smooth muscle, with consequent reduction in voiding pressure and urinary reflux, is other possible mechanisms for control of stent related symptoms, setting a rationale behind using alpha blockers in overcoming ureteral stent symptoms.
The Quality Of Life scores at pre-insertion and POD-1 in groups I to IV were nonsignificant i.e p value was 0.385 and 0.844 at pre-insertion and POD-1 respectively. At 2 weeks after insertion there was significant difference in scores (p value was 0.001) with minimum score in combination therapy and maximum score in control group.
The effectiveness of alpha blockers in controlling double-J stent-related symptoms was reported previously by Wang et al [19] in a prospective randomized study comparing tamsulosin to placebo in 79 patients using (USSQ) reported that tamsulosin improved stent related urinary symptoms, QoL, and they recommended its routine use.
Also Damiano et al [8] reported that administration of tamsulosin has a positive effect on stent-related urinary symptoms, QoL, and VAPS, although this study was not doubleblinded or placebo-controlled.
Also, several studies reported that other alphablocker alfuzosin improved stent-related symptoms and quality of life and reduced analgesic demand compared to the placebo group. [20, 21] Kuyumcuoglu et al [22] reported in a prospective randomized study that tamsulosin was not different than placebo in controlling stent-related symptoms. Similarly, Lee et al. [23] reported in a prospective, randomized, and placebo-controlled study that postoperative solifenacin use was effective and well tolerated for the treatment of LUTS, stent-related body pain, and hematuria irrespective of gender in patients undergoing ureteroscopic lithotripsy (URSL) and double-J stent indwelling.
CONCLUSION
Combination therapy with tamsulosin and solifenacin improved obstructive and irritative symptoms and QoL more than in the control group. Therefore, combination therapy with tamsulosin and solifenacin should be strongly considered for patients who complain of stentrelated symptoms. In the future, large-scale, prospective, and randomized study will be needed.
